-
Making Clinical Trials More Inclusive
Broadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.
by Ashley P. Taylor
-
Combining Treatment With Hospice Services
Organizations are testing new models of end-of-life care that allow patients to start hospice without stopping treatment.
by Cheryl Platzman Weinstock
-
The Education of a Patient Advocate
Bob Riter explains how his breast cancer diagnosis set him on a path to find his calling.
by Bob Riter
-
Survivor Profile
The Bridge BuilderBreast cancer survivor Bob Riter forges connections among people affected by all types of cancer.
by Marci A. Landsmann
-
Get Involved
That Rings a BellThe End of Treatment Bells fundraiser helps patients mark milestones.
by Sophy Ziss
-
Forward Look
Breaking Down Breakthrough Cancer TherapiesDrugs approved through this pathway may have limited evidence.
by Lindsey Konkel
-
Policy Matters
Public Funding is the Lifeblood of Cancer ResearchLet your voice be heard in support of robust, sustained and predictable federal funding increases.
by George D. Demetri, MD
-
Reinforcements for Cancer Research
Scientific meeting emphasizes the importance of patient advocates in helping researchers to reduce cancer health disparities.
by Marci A. Landsmann
-
Does Medicaid Expansion Have an Impact?
Analysis suggests states that opted for Medicaid expansion had higher use of hormone therapy for breast cancer patients.
by Marci A. Landsmann
-
Achieving Health Equality
National Cancer Institute director Norman “Ned” Sharpless describes the challenge and opportunity of studying cancer disparities.
by Marci A. Landsmann
Cancer Talk
Immunotherapy Improves Survival in Bladder Cancer
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff